CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study

Arai, Hiroyuki; Ishiguro, Koichi; Ohno, Hideto; Moriyama, Michiko; Itoh, Nobuo; Okamura, Nobuyuki; Matsui, Toshifumi; Morikawa, Yu Ichi; Horikawa, Etsuo; Kohno, Hideki; Sasaki, Hidetada; Imahori, Kazutomo

doi:10.1006/exnr.2000.7501

Cited by 114 publications

(69 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 Levels of p-tau doubly phosphorylated at threonine 231 and serine 235 were elevated in MCI subjects compared to controls with subjective memory complaints. 32 From that data and the results presented here, it might be assumed that among the three biomarkers Ab 1-42, ttau, and p-tau, t-tau might be the least sensitive to predict AD in MCI. In future studies, it has to be evaluated whether Ab 1-42 , t-tau or p-tau alone or a combination of the markers performs best to predict AD in MCI.…”

Section: Discussionsupporting

confidence: 54%

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel¹,

Teipel²,

Fuchsberger³

et al. 2003

Mol Psychiatry

285

196

View full text Add to dashboard Cite

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) bamyloid 1-42 (Ab 1-42 ) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Ab 1-42 and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Ab 1-42 and CSF tau. The levels of CSF tau were increased, whereas levels of Ab 1-42 were decreased in MCI subjects. Ab 1-42 predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Ab 1-42 , but not other predictor variables (tau protein, gender, age, apolipoprotein E e4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (Po0.05). Our findings support the notion that CSF tau and Ab 1-42 may be useful biomarkers in the early identification of AD in MCI subjects.

show abstract

Section: Discussionsupporting

confidence: 54%

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel¹,

Teipel²,

Fuchsberger³

et al. 2003

Mol Psychiatry

285

196

View full text Add to dashboard Cite

show abstract

“…CSF P-tau 199 measurement and determination of its phosphorylation, that seems precociously involved during AD pathogenesis and NFT formation (Maurage, Sergeant et al 2003), are able to discriminate AD patients from other degenerative dementias with a sensitivity and a specificity of 85% and 80% respectively (Itoh, Arai et al 2001). Phosphorylation of tau protein on both amino acid 231 and 235 might be predictive of MCI conversion into AD (Arai, Ishiguro et al 2000). In the same way, CSF level of P-tau 396/404 is elevated in AD compared to vascular dementia, and control subjects (Hu, He et al 2002).…”

Section: Which Csf Biochemical Markers Might Allow Us To Detect Alzhementioning

confidence: 99%

Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis

Elmoualij¹,

Dupiereux-Fettweis²,

Seguin³

et al. 2011

The Clinical Spectrum of Alzheimer's Disease -the Charge Toward Comprehensive Diagnostic and Therapeutic Strategies

View full text Add to dashboard Cite

“…CSF biomarkers for MCI include total tau protein (T-τ ), phosphorylated tau protein (P-τ ) and amyloid beta 1-42 protein (Aβ-42) [5,116]. Several studies have found high CSF T-τ and P-τ , and low CSF Aβ-42 in subjects with MCI, with sensitivity figures similar to, or slightly lower than, those found in AD cases [6,7,9,66].…”

Section: Biomarkersmentioning

confidence: 99%

Mild Cognitive Impairment: A Systematic Review

Mariani

Monastero

Mecocci

2007

JAD

210

182

View full text Add to dashboard Cite

Abstract. MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI (aMCI) characterized by reduced memory, and non-amnestic MCI (naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous -including vascular dementia, frontotemporal dementia or dementia with Lewy bodies-but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classification and prognosis, there is a need for more sensitive instruments specifically developed for MCI as well as for more reliable methods to determine its progression or improvement. Current clinical criteria for MCI should be updated to include restriction in complex ADL; also the diagnostic and prognostic role of behavioral symptoms and motor dysfunctions should be better defined. A multidisciplinary diagnostic approach including biological and neuroimaging techniques may probably represent the best option to predict the conversion from MCI to dementia. In this review we discuss the most recent aspects related to the epidemiological, clinical, neuropathological, neuroimaging, biochemical and therapeutic aspects of MCI, with specific attention to possible markers of conversion to dementia.

show abstract

CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study

Cited by 114 publications

References 13 publications

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis

Mild Cognitive Impairment: A Systematic Review

Contact Info

Product

Resources

About